
{"id":297651,"date":"2024-03-06T20:32:52","date_gmt":"2024-03-07T01:32:52","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=297651"},"modified":"2024-03-06T20:32:52","modified_gmt":"2024-03-07T01:32:52","slug":"how-close-is-cuba-to-having-a-dengue-vaccine","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/","title":{"rendered":"How close is Cuba to having a dengue vaccine?"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">On February 17, <\/span><a href=\"https:\/\/elpais.com\/planeta-futuro\/2024-02-17\/brasil-empieza-a-vacunar-del-dengue-en-la-sanidad-publica-en-medio-de-la-peor-epidemia-en-40-anos.html\" target=\"_blank\" rel=\"noopener\"><i><span style=\"font-weight: 400;\">El Pa\u00eds<\/span><\/i><\/a><span style=\"font-weight: 400;\">\u00a0reported that Brazil is experiencing the worst dengue epidemic in the last 90 years, with more than half a million patients and almost a hundred deaths from this disease. To face the crisis, health authorities decided to incorporate a vaccine into the dengue combat scheme.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The above makes Brazil the first country on the continent to use this health tool to combat the disease. The immunizer, purchased from the Japanese laboratory Takeda, began to be used in a clinical trial involving 20,000 people between 18 and 40 years old, who will receive two doses with an interval of three months between each one and will be followed for two years; well, although the drug has proven to be safe, it is not known for sure how it behaves in large population groups.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">With this, the vaccine, which has already been marketed in the Brazilian private network since 2023, is now extended to the public health system.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The idea is to administer the six million doses acquired, prioritizing children over 10 years of age<\/span><sup><b>1<\/b><\/sup><span style=\"font-weight: 400;\"> in the 541 cities with the highest incidence of cases. However, this is little for a country of 210 million inhabitants exposed to the disease.<\/span><\/p>\n<p><b>A disease that spreads on a global scale<\/b><\/p>\n<p><span style=\"font-weight: 400;\">According to the <\/span><a href=\"https:\/\/www.who.int\/es\/emergencies\/disease-outbreak-news\/item\/2023-DON498\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">WHO<\/span><\/a><span style=\"font-weight: 400;\">, in recent decades the number of reported cases of dengue has multiplied by 10, going from 500,000 to more than 5 million a year. The number of patients is probably between ten and twenty times greater.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">During 2020 and 2022, a decrease in the number of reported cases was observed. However, last year we witnessed a peak that approached historical highs, <\/span><a href=\"https:\/\/www.ecdc.europa.eu\/en\/all-topics-z\/dengue\/surveillance-and-disease-data\/autochthonous-transmission-dengue-virus-eueea\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">with outbreaks<\/span><\/a><span style=\"font-weight: 400;\"> in areas where it is not common. For example, in 2023, 43 cases were reported in France, 82 in Italy, and 3 in Spain, totaling 128 cases. So far this year, 312 cases <\/span><a href=\"https:\/\/www.cdc.gov\/dengue\/statistics-maps\/current-data.html\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">have been diagnosed<\/span><\/a><span style=\"font-weight: 400;\"> in the United States.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Although the state with the highest incidence is Florida, patients have also been reported far north of the subtropical belt in states such as Michigan, Illinois, New York, Montana, or Pennsylvania, close to Canada.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to the UN agency, the Americas region, with 4.1 million cases, led the world in terms of reporting the disease, accounting for nearly 80% of the total cases. In the region, an incidence of 416 cases per 100,000 inhabitants was also observed, more than 6,000 serious cases and 2,049 deaths, for a fatality rate of 0.05 per thousand patients. Additionally, 45% of the reported cases were confirmed by laboratory studies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Even though Cuba is not among the countries that reported the most cases nor those that reported the greatest number of serious illnesses or deaths to the international organization, on the island dengue is <\/span><a href=\"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/health-in-cuba\/preclinical-trials-begin-in-cuba-with-dengue-vaccine-candidate\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">a recurring problem<\/span><\/a><span style=\"font-weight: 400;\"> that the health authorities and, of course, the population have to confront. In fact, the incidence of the virus has sometimes been above 100 cases per 100,000 inhabitants.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Having a vaccine that prevents this disease is an old desire of Cuban scientists. Is this being worked on? How much progress has been made? How close is the country to having a dengue vaccine?<\/span><\/p>\n<p><b>On the trail of the Cuban vaccine<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Few diseases had as great an impact on Cuban public health during the second half of the 20th century as dengue. According to an <\/span><a href=\"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/15825\/v100n3p322.pdf?sequence=1&amp;isAllowed=y\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">article<\/span><\/a><span style=\"font-weight: 400;\">\u00a0by Dr. Gustavo Kour\u00ed, one of the world authorities on this disease, the Dengue Type 2 epidemic that devastated the country from the end of May to October 1981 left a total of more than 344,000 patients, with weeks of close to 10,000 cases. Of that total, about 9,000 suffered a severe form of the disease.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to the prominent virologist, 158 deaths were recorded, with a fatality rate of 0.46 per thousand patients, 101 of which were children. The ages where the highest number of deaths were concentrated were between 4 and 6 years old, which made this epidemic especially painful.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Since then, Cuban scientists such as Dr. Kour\u00ed and his wife, Dr. Mary Guzm\u00e1n, together with a group of prominent researchers, have contributed to elucidating different characteristics of the virus and the pathogenesis of the disease it causes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Their contributions have earned them important international awards, such as the <\/span><a href=\"https:\/\/www.rfi.fr\/es\/programas\/salud-y-bienestar\/20220630-la-cubana-mar%C3%ADa-guzm%C3%A1n-gana-el-premio-l-or%C3%A9al-unesco-2022-por-sus-investigaciones-sobre-el-dengue\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">2022 L\u2019Oreal<\/span><\/a><span style=\"font-weight: 400;\"> for Dr. Guzm\u00e1n, which she shared, among others, with last year\u2019s Nobel Prize winner in Medicine and Physiology, Dr. Katalin Karik\u00f3, to whom we dedicate <\/span><a href=\"https:\/\/oncubanews.com\/tendencias\/vida-saludable\/katalin-kariko-la-mujer-que-quiso-cambiar-el-mundo\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">an article<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to an <\/span><a href=\"https:\/\/www.swissinfo.ch\/spa\/el-camino-para-que-cuba-cree-la-primera-vacuna-latinoamericana-para-el-dengue\/48419974\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">article<\/span><\/a><span style=\"font-weight: 400;\"> in <\/span><i><span style=\"font-weight: 400;\">Swissinfo<\/span><\/i><span style=\"font-weight: 400;\">, since 1992 Cuban scientists have been searching for a dengue vaccine. For more than two decades, <\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X01005151\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">different compounds<\/span><\/a><span style=\"font-weight: 400;\"> have been tested that could lead to formulations capable of becoming a vaccine.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In 2006, a protein called <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16490289\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Domain III<\/span><\/a><span style=\"font-weight: 400;\"> caught the interest of the group of Cuban researchers from the Center for Genetic Engineering and Biotechnology (CIGB) and the Pedro Kour\u00ed Institute (IPK) who are working together in search of the immunizer. The compound\u2019s ability to generate immunity against dengue in primates was encouraging. New results on this line of research were published in <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18602424\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">2008<\/span><\/a><span style=\"font-weight: 400;\">\u00a0and <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19100804\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">2009<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In this way, the concept of a quadrivalent vaccine candidate was built, that is, capable of protecting against the four serotypes of the dengue virus, one of the golden goals for any vaccine that aims to be effective against the disease and something already achieved by the Takeda laboratory, mentioned at the beginning of the article.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In 2014, <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24841761\/\" target=\"_blank\" rel=\"noopener\"><b>a study<\/b><\/a><span style=\"font-weight: 400;\"> was published according to which a formulation based on the combination of different proteins present in areas of the virus structure, including Domain III, had the capacity to generate an immunological (defensive) response of the organism against the pathogen, making it viable as a vaccine candidate.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The formula, called TetraDIIIC, <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25795768\/\" target=\"_blank\" rel=\"noopener\"><b>was tested<\/b><\/a><span style=\"font-weight: 400;\"> in 2015 in mice and non-human primates, obtaining encouraging results. In the following years, experiments were carried out to determine which doses allowed the best immunological response to be obtained in laboratory animals and the results <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28393307\/\" target=\"_blank\" rel=\"noopener\"><b>were published<\/b><\/a><span style=\"font-weight: 400;\"> in 2017, through several <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28418786\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">articles<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In <\/span><a href=\"https:\/\/elfosscientiae.cigb.edu.cu\/PDFs\/Biotecnol%20Apl\/2020\/37\/1\/BA003701RP1501-1504.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">2019<\/span><\/a><span style=\"font-weight: 400;\">, a work in which the strategy of combining the vaccine candidate, TetraDIIIC, to which we have been referring, with another tetravalent candidate of attenuated viruses, known as TV005, developed by the U.S. National Institute of Allergy and Infectious Diseases.<\/span><sup><b>2<\/b><\/sup><span style=\"font-weight: 400;\"> In this case, instead of the protein-based compound, a formulation containing weakened viruses of the four serotypes of dengue was used.<\/span><\/p>\n<p><b>A new strategy?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">In September 2022, <\/span><a href=\"http:\/\/cuba.cu\/salud\/2022-09-22\/presentan-en-cuba-estrategia-para-creacion-de-vacuna-contra-dengue\/60875\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">national media<\/span><\/a><span style=\"font-weight: 400;\"> briefly reported on the presentation by Dr.S. Gerardo Guill\u00e9n Nieto \u2014 member of the team of researchers in charge of the development of the vaccine since the first published works and director of Biomedical Research at the CIGB \u2014 on \u201cthe Cuban strategy for the dengue vaccine\u201d before the highest authorities of the country.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In March 2023, the CIGB reported through the <\/span><a href=\"https:\/\/twitter.com\/CIGBCuba\/status\/1638099878839738368?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1638099878839738368%7Ctwgr%5Ead71ca3c3a1b4a78f375a217df5eef76763790dc%7Ctwcon%5Es1_&amp;ref_url=http%3A%2F%2Fwww.cubadebate.cu%2Fnoticias%2F2023%2F03%252\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">X social media<\/span><\/a><span style=\"font-weight: 400;\"> that the Cuban strategy to obtain a vaccine against this disease is based on recombinant proteins, but on this occasion, they were referring to the use of different structures than the one they were following with TetraDIIIC. According to the institution\u2019s publication, it is \u201ca very secure technological platform. We have a tetravalent candidate, based on proteins from the four dengue viruses, that we are evaluating at this moment.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A month later, the aforementioned scientific institution <\/span><a href=\"https:\/\/twitter.com\/CIGBCuba\/status\/1642899504994066435?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1642899504994066435%7Ctwgr%5E80df8abe62f3355ba92faff3ffc881027dd0185a%7Ctwcon%5Es1_&amp;ref_url=http%3A%2F%2Fwww.cubadebate.cu%2Fnoticias%2F2023%2F04%252\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">announced<\/span><\/a><span style=\"font-weight: 400;\"> that the vaccine candidate against dengue is currently in the \u201cresearch-development stage.\u201d According to the publication, the researchers \u201care beginning preclinical studies, where they are testing 2 different formulations, intending to determine which one will be taken to clinical studies,\u201d that is, which one will be tested in humans.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On that same date, in an <\/span><a href=\"https:\/\/www.swissinfo.ch\/spa\/el-camino-para-que-cuba-cree-la-primera-vacuna-latinoamericana-para-el-dengue\/48419974\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">interview<\/span><\/a><span style=\"font-weight: 400;\">\u00a0given to EFE and reproduced by <\/span><i><span style=\"font-weight: 400;\">Swissinfo<\/span><\/i><span style=\"font-weight: 400;\">, the CIGB research director explained that \u201cinstead of using the protein found in the virus membrane,\u201d Cuban researchers \u201care experimenting with its non-structural proteins (which encode the genes of the virus).\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to Guill\u00e9n Nieto, what they are pursuing is to create a vaccine capable of strengthening the cell-mediated response in the person who receives it and not that of their antibodies. What does this mean?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The body\u2019s immune response is made up of two fundamental branches: the humoral response and the cellular response. A <\/span><a href=\"https:\/\/medicina.udd.cl\/42657-2\/#:~:text=La%20respuesta%20humoral%20es%20la,organismo%20donde%20puede%20haber%20infecci%C3%B3n.\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">humoral response<\/span><\/a><span style=\"font-weight: 400;\"> is understood as the body\u2019s way of dealing with toxins and infections through antibodies, which are proteins specifically designed against different antigens and transported by the blood, something like the infantry of the immune system.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">They have the function of preventing the infection from entering the cells and multiplying. It is important to remember that viruses need the cellular apparatus to replicate.<\/span><\/p>\n<p><a href=\"https:\/\/www.unilabs.es\/glosario\/inmunidad-celular#:~:text=La%20inmunidad%20celular%20es%20un,y%20no%20por%20los%20anticuerpos.\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Cellular immunity<\/span><\/a><span style=\"font-weight: 400;\"> is focused on eliminating different enemies through the direct action of the cells of the immune system, such as T lymphocytes, which would be the motorized artillery and aviation of our defensive system. These cells have the ability to identify and eliminate infected cells, without attacking healthy ones or causing very little damage. It is a second line of defense against antibody-mediated immunity, which it completes and complements.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Does this new bet in the development of the Cuban vaccine mean abandoning years of research and starting a new path to obtain an efficient immunizer? What is this about? The answer is not clear. Based on more recent announcements, the Cuban team decided to put aside the line of research on the TetraDIIIC vaccine candidate.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In fact, since 2019, after intense activity in previous years with dozens of scientific articles on this line, the number of publications with the domain \u201cCuba dengue vaccine\u201d on the <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=cuba+vaccine+dengue&amp;filter=years.2021-2021\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Pubmed<\/span><\/a><span style=\"font-weight: 400;\">\u00a0site decreased drastically, finding only 6 between 2020 and 2023. On the other hand, since that year, <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=TetraDIIIC\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">publications<\/span><\/a><span style=\"font-weight: 400;\">\u00a0with the TetraDIIIC domain have not been collected on the same specialized site.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This may have to do with the safety profile of the Cuban candidate and may be related to what happened with Dengvaxia, the first approved dengue vaccine in the world, to which the CIGB research director refers in the <\/span><i><span style=\"font-weight: 400;\">Swissinfo<\/span><\/i><span style=\"font-weight: 400;\"> publication.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dengvaxia is an immunizer developed by a French pharmaceutical company based in the United States, Sanofi Pasteur. In 2017, after having vaccinated more than 733,000 minors in the Philippines, its administration was prohibited in that country, after the death of children with severe forms of the disease was recorded. Based on that, the FDA, the U.S. regulatory agency, ordered the suspension of all \u201csale, marketing, and marketing operations\u201d of the product and \u201cinitiating an information campaign about the risks,\u201d according to an <\/span><a href=\"https:\/\/www.elmundo.es\/ciencia-y-salud\/salud\/2017\/12\/07\/5a293fe6268e3e1d418b4578.html\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">article<\/span><\/a><span style=\"font-weight: 400;\"> in <\/span><i><span style=\"font-weight: 400;\">El Mundo<\/span><\/i><span style=\"font-weight: 400;\">, generating a great deal of scandal with multiple implications.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Why was this vaccine unsafe? Everything seems to indicate that it is due to a phenomenon known as antibody-dependent amplification (<\/span><a href=\"http:\/\/scielo.sld.cu\/scielo.php?script=sci_arttext&amp;pid=S0375-07602004000300008\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ADA<\/span><\/a><span style=\"font-weight: 400;\">), which is characteristic of this disease. When a person is infected by a virus of one of the four dengue serotypes, say 1, the infection is usually asymptomatic or very mild.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">However, if a person becomes infected in the future with a virus of any of the other serotypes, then there is a possibility that instead of a banal infection, a severe form of the disease will appear, which can lead to death. This happens because antibodies, that first line of defense, instead of protecting the body against infection, induce an exaggerated response.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Returning to Dr. Guill\u00e9n Nieto\u2019s <\/span><a href=\"https:\/\/www.swissinfo.ch\/spa\/el-camino-para-que-cuba-cree-la-primera-vacuna-latinoamericana-para-el-dengue\/48419974\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">interview<\/span><\/a><span style=\"font-weight: 400;\">, \u201cCuba seeks to make the vaccine in a different way\u201d and, according to the expert, \u201cit is the only country that is trying to do it this way,\u201d experimenting with non-structural proteins, that is, they are not part of the virus envelope, but are encoded by its genes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">So that it is understood, the virus is known as a <\/span><a href=\"https:\/\/genotipia.com\/virus-estructura\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">\u201cvirion\u201d<\/span><\/a><span style=\"font-weight: 400;\"> when it has not infected the cell. The virion is DNA or RNA (genetic information) that encodes the proteins responsible for the activity of the virus, covered by different molecules that make up a structure called capsid. These molecules are known as capsomers and are responsible for protecting the viral core.<\/span><\/p>\n<p><a href=\"https:\/\/decs.bvsalud.org\/es\/ths\/resource\/?id=30463\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Non-structural proteins<\/span><\/a><span style=\"font-weight: 400;\"> are contained in the genetic information carried by the virus and have different functions. Viruses need the cell\u2019s assembly machinery to reproduce or replicate.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This would avoid ADA or immunoamplification, as the phenomenon is also known, generating an important cellular response that would prevent severe forms of dengue. According to the CIGB research director, what is sought is that the \u201ccellular response is sufficient to protect (from the four serotypes). We are going to have a safety guarantee, but it remains to be demonstrated whether we are going to be sufficiently effective to protect against the disease.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In the near future, there will surely be more information on this topic. At the moment, there is a precedent for a 2014 <\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s11262-014-1087-3\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">publication<\/span><\/a><span style=\"font-weight: 400;\"> in which antigenicity (the ability to produce an immune response in the body) and immunogenicity were studied, which is related to the immunological memory of the recombinant non-structural protein 3 (NS3) of dengue.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Be that as it may, it is a fact that Cuban scientists have worked for decades to obtain a vaccine against the four serotypes of the dengue virus. The path has been complex, not only for the island\u2019s researchers but for all those who have tried to find the precious formulation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">As we saw, there are only two approved vaccines in the world: Dengvaxia, from a French laboratory, whose safety problems have considerably limited its marketing, and Qdenga, as the Japanese vaccine is also known, whose cost per dose, according to <\/span><a href=\"https:\/\/www.lanacion.com.ar\/sociedad\/vacuna-contra-el-dengue-cual-es-el-precio-y-donde-conseguirla-nid27122023\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">an Argentine newspaper<\/span><\/a><span style=\"font-weight: 400;\">, is 52 dollars. Qdenga manufacturers cannot meet the demand of a country like Brazil,<\/span><sup><b>3<\/b><\/sup><span style=\"font-weight: 400;\"> much less that of nearly 50% of the world\u2019s population exposed to the virus.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In this way, the strategy of having a nationally produced compound in Cuba would be extraordinary from many points of view. Firstly, the country would greatly reduce the costs of immunizing its population. On the other hand, it would enter a market of billions of people in the world who are exposed to dengue throughout the tropical and subtropical belt, which would bring obvious economic benefits.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">However, the achievement of a Cuban antigen against dengue will take time. To give you an idea, only phase III studies last between 3 and 5 years in the case of vaccine candidates against this disease and are the last step in the long process of research and development of an immunizer, which in the conditions in Cuba, according to CIGB authorities, are made more complex by <\/span><a href=\"https:\/\/www.swissinfo.ch\/spa\/el-camino-para-que-cuba-cree-la-primera-vacuna-latinoamericana-para-el-dengue\/48419974\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">U.S. regulations<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">But the longest path begins with the first step, no matter how many times it is necessary to take it.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">________________________________________<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Notes:<\/span><\/i><\/p>\n<p><sup><b>1<\/b><\/sup><span style=\"font-weight: 400;\"> Children are one of the most important risk groups for dengue, with one of the highest mortality rates, as was the case in the 1981 Cuban epidemic.<\/span><\/p>\n<p><sup><b>2<\/b><\/sup><span style=\"font-weight: 400;\"> This research was jointly conducted by Cuban researchers from CIGB and IPK, Vietnamese researchers from the Center for Vaccine Research POLYVAC and the vaccine production company VABIOTECH. Through the latter, the license was obtained for the use of the vaccine candidate being developed by the National Institute of Health (NIH) of the United States. The U.S. side obtained from this investigation valuable information about the use of its candidate in conjunction with other preparations in a strategy that may be novel and useful. This is an example of international cooperation in the field of science.<\/span><\/p>\n<p><sup><b>3<\/b><\/sup><span style=\"font-weight: 400;\"> As it is a vaccine made from attenuated viruses, producing this type of immunizer is much more complex than producing recombinant protein or RNA vaccines. Due to the country\u2019s demand, the Japanese do not have the capacity to produce the 420 million dengue vaccines that a nation like Brazil needs.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.<\/p>\n","protected":false},"author":12345834,"featured_media":297653,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13918,14135],"tags":[28686,25615,19256],"ppma_author":[34560],"class_list":["post-297651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-in-cuba","category-opinion","tag-biotechnology-in-cuba","tag-dengue","tag-featured"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>How close is Cuba to having a dengue vaccine? | OnCubaNews English<\/title>\n<meta name=\"description\" content=\"Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How close is Cuba to having a dengue vaccine? | OnCubaNews English\" \/>\n<meta property=\"og:description\" content=\"Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"OnCubaNews English\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-07T01:32:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2024\/03\/importancia-da-vacinacao-contra-dengue-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1422\" \/>\n\t<meta property=\"og:image:height\" content=\"738\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Carlos Alberto Gonz\u00e1lez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carlos Alberto Gonz\u00e1lez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/\"},\"author\":{\"name\":\"carlosalbertogonzalez\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/2c76245ec7769cd9f458b8f35d9c6439\"},\"headline\":\"How close is Cuba to having a dengue vaccine?\",\"datePublished\":\"2024-03-07T01:32:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/\"},\"wordCount\":2539,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/importancia-da-vacinacao-contra-dengue-1.jpg\",\"keywords\":[\"biotechnology in Cuba\",\"Dengue\",\"featured\"],\"articleSection\":[\"Health in Cuba\",\"Opinion\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/\",\"name\":\"How close is Cuba to having a dengue vaccine? | OnCubaNews English\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/importancia-da-vacinacao-contra-dengue-1.jpg\",\"datePublished\":\"2024-03-07T01:32:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/2c76245ec7769cd9f458b8f35d9c6439\"},\"description\":\"Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/importancia-da-vacinacao-contra-dengue-1.jpg\",\"contentUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/importancia-da-vacinacao-contra-dengue-1.jpg\",\"width\":1422,\"height\":738,\"caption\":\"Photo: Taken from Hermes Pardini (online).\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/opinion\\\/how-close-is-cuba-to-having-a-dengue-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How close is Cuba to having a dengue vaccine?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\",\"name\":\"OnCubaNews English\",\"description\":\"Revista sobre Cuba\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/2c76245ec7769cd9f458b8f35d9c6439\",\"name\":\"carlosalbertogonzalez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g96692c05f4b2ce956c2e5f967d928992\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g\",\"caption\":\"carlosalbertogonzalez\"},\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/author\\\/carlosalbertogonzalez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How close is Cuba to having a dengue vaccine? | OnCubaNews English","description":"Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"How close is Cuba to having a dengue vaccine? | OnCubaNews English","og_description":"Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.","og_url":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/","og_site_name":"OnCubaNews English","article_published_time":"2024-03-07T01:32:52+00:00","og_image":[{"width":1422,"height":738,"url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2024\/03\/importancia-da-vacinacao-contra-dengue-1.jpg","type":"image\/jpeg"}],"author":"Carlos Alberto Gonz\u00e1lez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Carlos Alberto Gonz\u00e1lez","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#article","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/"},"author":{"name":"carlosalbertogonzalez","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439"},"headline":"How close is Cuba to having a dengue vaccine?","datePublished":"2024-03-07T01:32:52+00:00","mainEntityOfPage":{"@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/"},"wordCount":2539,"commentCount":0,"image":{"@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2024\/03\/importancia-da-vacinacao-contra-dengue-1.jpg","keywords":["biotechnology in Cuba","Dengue","featured"],"articleSection":["Health in Cuba","Opinion"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/oncubanews.com\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/","url":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/","name":"How close is Cuba to having a dengue vaccine? | OnCubaNews English","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2024\/03\/importancia-da-vacinacao-contra-dengue-1.jpg","datePublished":"2024-03-07T01:32:52+00:00","author":{"@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439"},"description":"Having an immunizer that prevents this disease is an old desire of Cuban scientists, who have been working on it since 1992.","breadcrumb":{"@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#primaryimage","url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2024\/03\/importancia-da-vacinacao-contra-dengue-1.jpg","contentUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2024\/03\/importancia-da-vacinacao-contra-dengue-1.jpg","width":1422,"height":738,"caption":"Photo: Taken from Hermes Pardini (online)."},{"@type":"BreadcrumbList","@id":"https:\/\/oncubanews.com\/en\/opinion\/how-close-is-cuba-to-having-a-dengue-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/oncubanews.com\/en\/"},{"@type":"ListItem","position":2,"name":"How close is Cuba to having a dengue vaccine?"}]},{"@type":"WebSite","@id":"https:\/\/oncubanews.com\/en\/#website","url":"https:\/\/oncubanews.com\/en\/","name":"OnCubaNews English","description":"Revista sobre Cuba","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oncubanews.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439","name":"carlosalbertogonzalez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g96692c05f4b2ce956c2e5f967d928992","url":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g","caption":"carlosalbertogonzalez"},"url":"https:\/\/oncubanews.com\/en\/author\/carlosalbertogonzalez\/"}]}},"authors":[{"term_id":34560,"user_id":12345834,"is_guest":0,"slug":"carlosalbertogonzalez","display_name":"Carlos Alberto Gonz\u00e1lez","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/297651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/users\/12345834"}],"replies":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/comments?post=297651"}],"version-history":[{"count":2,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/297651\/revisions"}],"predecessor-version":[{"id":297658,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/297651\/revisions\/297658"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media\/297653"}],"wp:attachment":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media?parent=297651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/categories?post=297651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/tags?post=297651"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/ppma_author?post=297651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}